Free shipping for orders over $40!


No products in the cart.

Zoono Group Limited (ASX: ZNO)


With the recent emergence in China of a new virulent strain of the coronavirus, and the well-publicised impacts of that virus on human health, Zoono Group Limited (ASX:ZNO) has been inundated by public and shareholder enquiry concerning its products and their effectiveness in combatting the spread of the new virus.

Zoono is confident that it is extremely well positioned to be part of the solution to both coronavirus and other new virus threats. The Zoono technology, particularly its longevity and killing methodology, delivers an ideal solution.

Zoono’s Z71 Microbe Shield Surface Sanitiser was successfully tested in 2014 against bovine coronavirus (i.e. a surrogate recognised by the World Health Organisation for other members of the coronaviridae family, including the MERS virus (CoV-MERS)). Test results confirmed a 99.99% efficacy in five minutes.

Zoono’s Z71 Microbe Shield Surface Sanitiser and GermFree24 Hand Sanitiser products were recently sent to a German laboratory for testing against the latest Chinese strain of the coronavirus (2019-nCoV). This strain of the coronavirus has not previously been available for testing. Given the successful test results in 2014 and since, Zoono is very confident that both products will have a level of efficacy against the current strain of the coronavirus similar to that achieved previously. Both contain the same active ingredient. Results from testing against the current coronavirus strain are expected in the next four to six weeks.

Operationally, once the impact of the new coronavirus emerged, Zoono made an immediate decision in early January to ramp up production of its key active ingredients and its Z71 Microbe Shield Surface Sanitiser and GermFree24 Hand Sanitiser finished goods.

This decision has proved to be very prescient as this month has seen:

      • Product orders in excess of NZ$1M received in the last two weeks of January, predominately from China and Hong Kong
      • Online consumer sales up significantly with a record day recently of $49,000 in one day
      • Forward orders and product inquiries increasingly strong, with particular interest from major companies in new distribution arrangements and the introduction of Zoono products into different vertical markets

Zoono expects to be able to meet the increased demand for its products.

This announcement has been approved and authorised for release by the Board of Zoono Group Limited.

For further information, please contact:

Zoono Group Limited
Paul Hyslop
Managing Director/CEO
M: +64 21 659 977
E: [email protected]

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono’s mission is to improve health and well-being through innovative, safe, nontoxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the ‘zoono molecule’, a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono’s products have received numerous regulatory approvals and the company’s technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally. To learn more, please visit:

Send this to a friend